Two wrong responses:
First of all this ain’t the flu. Many people with underlying heath issues and the elderly are becoming grossly ill due to COVID. Even though many healthy persons are not affected it is wise to take precautions to not spread COVID.
Secondly, Tro xr will never “make up ground” on the “other brands”. This doesn’t mean we can’t grow both products by getting out in the field and selling but Tro xr has been labeled from day one as a better QD option with better AEs. These benefits have been further etched in stone when we got migraine indication. When we started selling actual migraine reduction improvements for patients on Ir to switch to Tro xr we started to get some of those scripts (with GC help), then guess what happened....the difference in migraine reduction between Ir and Tro xr was minimal. Majority of patients didn’t become migraine free or get migraines cut in half like our pragmatic assessment said. So Tro xr went back to being a new start option or AE solution. Cgrp comes out with tremendous hype and based on feedback from Drs the hype is real. Migraines are improved and cgrp ain’t killing anyone out there. So naturally when you have a product that solves the problem that the majority of the market is craving, the product explodes. All the marketing in the world or the 1000 POAs wouldn’t have made Tro xr a blockbuster. Let’s be honest with ourselves here and it would save a bunch of grief in the long run. With this being said we can still grow Tro xr. GC scripts will eventually die off and our TRUE national MS will be the correct baseline. And even better the company will actually make profit on the scripts we sell instead of giving them away with GC. Have a great day everyone!